Million-dollar investment to bring quantum technology closer to the next generation of medicine

The Aarhus-based quantum scaleup Kvantify has completed the second closing of a total funding round of EUR 7 million. The investment will be used to accelerate the development of technology that combines quantum and classical computing in molecular design and drug development.

“We are very pleased to have EIC Fund and Delphinus Venture Capital join us in this expansion round. Their support allows us to accelerate innovation and strengthen Europe’s position in quantum technology,” says Dr. Jörg Weiser, Executive Chairperson of Kvantify.

Investors include the European Innovation Council Fund and the Aarhus-based venture fund Delphinus Ventures Capital, both of which support the company’s ambition to transform molecular research by combining quantum and classical computing.

Quantum computing can change drug development

Quantum technology is increasingly seen as a key to solving computational problems that today are too complex for even the most advanced classical computers.

Especially in drug development, quantum computing can be of great importance. Many challenges in drug discovery involve molecular simulations, where researchers must solve quantum mechanical equations that grow exponentially in complexity as molecules become larger.

These types of problems were part of the original motivation behind the development of quantum computers. As hardware and algorithms mature, the technology has the potential to reduce error rates in drug development, lower research costs and open the door to entirely new types of medicine.

“Supporting breakthrough technologies is at the heart of our mission. Quantify’s work at the intersection of quantum computing and life science represents a transformative opportunity for Europe to take the lead in next generation innovation. We are excited to help accelerate this vision,” says Svetoslava Georgieva, Chair of the EIC Fund Board.

Platform to bring technology to users

As part of its strategy, in November 2025, Kvantify launched Qrunch technology, a platform designed to run quantum chemistry on real quantum computers.

The goal is to make advanced quantum computing available in realistic workflows for researchers and companies in the pharmaceutical and other industries. The platform makes it possible to combine today’s quantum hardware with classical computational methods.

With the new investment, the company will expand its market position and increase collaboration with drug discovery organizations. The ambition is to strengthen the company’s position as a leading player in the integration of quantum and classical computing.

“We see Kvantify as a key player in realizing the potential of quantum computing for concrete applications in drug development and molecular design. The investment reflects our confidence in the team, the technology and their ability to create real value in a rapidly evolving market,” says Mathias Lorenz, Managing Partner at Delphinus.